|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2011-1-5
|
|
pubmed:abstractText |
Phase III trials of the anti-insulin-like growth factor type 1 receptor (IGF-IR) antibody figitumumab (F) in unselected non-small-cell lung cancer (NSCLC) patients were recently discontinued owing to futility. Here, we investigated a role of free IGF-1 (fIGF-1) as a potential predictive biomarker of clinical benefit from F treatment.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Cadherins,
http://linkedlifedata.com/resource/pubmed/chemical/Carboplatin,
http://linkedlifedata.com/resource/pubmed/chemical/Insulin,
http://linkedlifedata.com/resource/pubmed/chemical/Insulin-Like Growth Factor Binding...,
http://linkedlifedata.com/resource/pubmed/chemical/Insulin-Like Growth Factor I,
http://linkedlifedata.com/resource/pubmed/chemical/Paclitaxel,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Markers, Biological,
http://linkedlifedata.com/resource/pubmed/chemical/figitumumab
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
1532-1827
|
|
pubmed:author |
pubmed-author:BlakelyJJ,
pubmed-author:Dolled-FilhartMM,
pubmed-author:GreenSS,
pubmed-author:GualbertoAA,
pubmed-author:HixonM LML,
pubmed-author:KarpD DDD,
pubmed-author:LUPP,
pubmed-author:LangerC JCJ,
pubmed-author:NovelloSS,
pubmed-author:Paz-AresL GLG,
pubmed-author:PollakM NMN
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
4
|
|
pubmed:volume |
104
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
68-74
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:21102589-Adult,
pubmed-meshheading:21102589-Aged,
pubmed-meshheading:21102589-Aged, 80 and over,
pubmed-meshheading:21102589-Antibodies, Monoclonal,
pubmed-meshheading:21102589-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:21102589-Cadherins,
pubmed-meshheading:21102589-Carboplatin,
pubmed-meshheading:21102589-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:21102589-Clinical Trials, Phase II as Topic,
pubmed-meshheading:21102589-Enzyme-Linked Immunosorbent Assay,
pubmed-meshheading:21102589-Female,
pubmed-meshheading:21102589-Follow-Up Studies,
pubmed-meshheading:21102589-Humans,
pubmed-meshheading:21102589-Insulin,
pubmed-meshheading:21102589-Insulin-Like Growth Factor Binding Protein 1,
pubmed-meshheading:21102589-Insulin-Like Growth Factor I,
pubmed-meshheading:21102589-Lung Neoplasms,
pubmed-meshheading:21102589-Male,
pubmed-meshheading:21102589-Middle Aged,
pubmed-meshheading:21102589-Multicenter Studies as Topic,
pubmed-meshheading:21102589-Neoplasm Staging,
pubmed-meshheading:21102589-Paclitaxel,
pubmed-meshheading:21102589-Randomized Controlled Trials as Topic,
pubmed-meshheading:21102589-Survival Rate,
pubmed-meshheading:21102589-Treatment Outcome,
pubmed-meshheading:21102589-Tumor Markers, Biological
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab.
|
|
pubmed:affiliation |
The Department of Clinical Development and Medical Affairs, Pfizer Oncology, New London, CT 06320, USA. antonio.gualberto@mpi.com
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|
